| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 6/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
BDSI Overview
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally.
BioDelivery Sciences International Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.99 |
| 52 Week High | US$3.04 |
| 52 Week Low | US$4.99 |
| Beta | 0.70 |
| 1 Month Change | 16.33% |
| 3 Month Change | 9.62% |
| 1 Year Change | -1.97% |
| 3 Year Change | 40.00% |
| 5 Year Change | 47.78% |
| Change since IPO | 20.91% |
Recent News & Updates
BioDelivery Sciences: Legal Fees Are Causing My Pain
Share price performance has been a massive disappointment since I last covered the stock. I provide my updated valuation of BDSI to represent the acquisition of US and Canadian rights to ELYXYB. My model shows shares are trading at a discount of ~67%. Litigation costs and risks are mounting and seem to be the main culprit for the discount to fair value.
BioDelivery Sciences: Yet Another Buying Opportunity
BDSI trades at extremely low P/E and EV/S ratios for a company that is still growing at a good clip. Management has cleared up a few concerns by finally starting the process of buying back shares and stopping the dilution that happened for so long. The largest risk remains ongoing litigation with AQST.
Does BioDelivery Sciences International (NASDAQ:BDSI) Deserve A Spot On Your Watchlist?
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
Shareholder Returns
| BDSI | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -6.8% | -2.5% | -0.6% |
| 1Y | -2.0% | 11.0% | 33.8% |
Return vs Industry: BDSI underperformed the US Pharmaceuticals industry which returned 11% over the past year.
Return vs Market: BDSI underperformed the US Market which returned 33.8% over the past year.
Price Volatility
| BDSI volatility | |
|---|---|
| BDSI Beta | 0.70 |
| Industry Beta | 0.64 |
| Market Beta | 1 |
Stable Share Price: BDSI is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: BDSI's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 176 | Jeff Bailey | https://www.bdsi.com |
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug-delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film to treat opioid dependence; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients.
Valuation
Is BioDelivery Sciences International undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: BDSI ($3.99) is trading below our estimate of fair value ($33.06)
Significantly Below Fair Value: BDSI is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: BDSI is good value based on its PE Ratio (11.6x) compared to the US Pharmaceuticals industry average (22.9x).
PE vs Market: BDSI is good value based on its PE Ratio (11.6x) compared to the US market (17.8x).
Price to Earnings Growth Ratio
PEG Ratio: BDSI is good value based on its PEG Ratio (0.3x)
Price to Book Ratio
PB vs Industry: BDSI is overvalued based on its PB Ratio (3.5x) compared to the US Pharmaceuticals industry average (3.3x).
Future Growth
How is BioDelivery Sciences International forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
39.0%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BDSI's forecast earnings growth (39% per year) is above the savings rate (2%).
Earnings vs Market: BDSI's earnings (39% per year) are forecast to grow faster than the US market (14.9% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: BDSI's revenue (18.2% per year) is forecast to grow faster than the US market (9.8% per year).
High Growth Revenue: BDSI's revenue (18.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BDSI's Return on Equity is forecast to be high in 3 years time
Past Performance
How has BioDelivery Sciences International performed over the past 5 years?
41.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BDSI has high quality earnings.
Growing Profit Margin: BDSI's current net profit margins (20.7%) are higher than last year (4.2%).
Past Earnings Growth Analysis
Earnings Trend: BDSI has become profitable over the past 5 years, growing earnings by 41% per year.
Accelerating Growth: BDSI's earnings growth over the past year (485.3%) exceeds its 5-year average (41% per year).
Earnings vs Industry: BDSI earnings growth over the past year (485.3%) exceeded the Pharmaceuticals industry 17.5%.
Return on Equity
High ROE: BDSI's Return on Equity (29.7%) is considered high.
Financial Health
How is BioDelivery Sciences International's financial position?
Financial Position Analysis
Short Term Liabilities: BDSI's short term assets ($196.1M) exceed its short term liabilities ($63.9M).
Long Term Liabilities: BDSI's short term assets ($196.1M) exceed its long term liabilities ($72.5M).
Debt to Equity History and Analysis
Debt Level: BDSI's debt to equity ratio (69%) is considered high.
Reducing Debt: BDSI's debt to equity ratio has reduced from 445.2% to 69% over the past 5 years.
Debt Coverage: BDSI's debt is well covered by operating cash flow (51.3%).
Interest Coverage: BDSI's interest payments on its debt are well covered by EBIT (5.3x coverage).
Balance Sheet
Dividend
What is BioDelivery Sciences International current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BDSI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BDSI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BDSI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BDSI's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BDSI's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.8yrs
Average management tenure
CEO
Jeff Bailey (58 yo)
1.33yrs
Tenure
US$3,953,210
Compensation
Mr. Jeffrey Allen Bailey, also known as Jeff, has been Chief Executive Officer at BioDelivery Sciences International, Inc. since November 4, 2020. Mr. Bailey served as Interim Chief Executive Officer at Bi...
CEO Compensation Analysis
Compensation vs Market: Jeff's total compensation ($USD3.95M) is above average for companies of similar size in the US market ($USD1.67M).
Compensation vs Earnings: Insufficient data to compare Jeff's compensation with company performance.
Leadership Team
Experienced Management: BDSI's management team is considered experienced (2.8 years average tenure).
Board Members
Experienced Board: BDSI's board of directors are considered experienced (3.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
BioDelivery Sciences International, Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: BioDelivery Sciences International, Inc.
- Ticker: BDSI
- Exchange: NasdaqGS
- Founded: 1997
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$393.404m
- Shares outstanding: 98.60m
- Website: https://www.bdsi.com
Number of Employees
Location
- BioDelivery Sciences International, Inc.
- 4131 ParkLake Avenue
- Suite 225
- Raleigh
- North Carolina
- 27612
- United States
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/09/18 22:16 |
| End of Day Share Price | 2021/09/17 00:00 |
| Earnings | 2021/06/30 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.